Head of Performance Marketing

Dr. Steven steinhubl joins Eko Health as chief medical officer. New hire will help advance clinical innovation and global impact of AI-enabled cardiac detection. July 24, 2026 Managing Editor Eko Health has appointed Steven R. Steinhubl, M.D., as chief medical officer (CMO) and member of the executive leadership team. In his new role, Dr. Steinhubl will help drive Eko's clinical strategy, research initiatives, and external scientific collaborations, further strengthening the evidence base and accelerating artificial intelligence (AI) adoption across health systems worldwide. His multidisciplinary background spanning engineering, physiology, and medicine positions him to bridge technology innovation with practical clinical application, executives claim. "Steve understands both the clinical realities of cardiovascular care and the promise of new technologies to improve it," Eko Health Co-Founder/CEO Connor Landgraf stated. "As Eko expands the global reach of AI-powered cardiac detection, his leadership will help ensure our work continues to translate into meaningful outcomes for clinicians and the patients they serve." Dr. Steinhubl is currently the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University in the Weldon School of Biomedical Engineering and is a member of the Regenstrief Center for Healthcare Engineering in West Lafayette, Ind. A globally recognized cardiologist, clinical researcher, and digital medicine pioneer, Dr. Steinhubl has dedicated his career to advancing cardiovascular care through the integration of wearable technologies, AI, and virtual-first care models. Dr. Steinhubl's research focuses on personal wearable sensor technologies, artificial intelligence and machine learning in healthcare, precision communication strategies in digital health, virtual-first care delivery, and the use of digital technologies to address health inequities. Over the course of his career, he has authored peer-reviewed publications and led large-scale clinical research initiatives aimed at improving early detection and prevention of cardiovascular disease. "As a clinician and researcher, I've long believed that the future of cardiovascular care lies in combining high-fidelity physiological data with intelligent analytics delivered seamlessly at the point of care," Dr. Steinhubl said. "Eko's platform represents a powerful step toward that future. By embedding AI into a tool clinicians already use every day, we can support earlier recognition of cardiac risk without disrupting workflow. I'm excited to help expand the scientific foundation, clinical partnerships, and real-world impact of this technology." Dr. Steinhubl's appointment arrives amid accelerating clinical and commercial momentum for Eko Health. Over the past year: * CMS finalized national payment for Eko Health's SENSORA platform under the Outpatient Prospective Payment System (OPPS). * Former U.S. Surgeon General Dr. Jerome Adams joined Eko Health as Distinguished Medical Advisor * The company reported results from the independently run landmark TRICORDER study published in The Lancet. Eko Health expanded deployment of its platform through new health system partnerships, including a recent rollout at Wayne General Hospital aimed at improving access to earlier cardiovascular screening in rural communities. Internationally, Eko Health launched its AI-powered stethoscope platform in the United Kingdom and expanded into Canada following Health Canada clearance of the CORE 500 Digital Stethoscope. Together, these milestones reflect growing global adoption of AI-assisted auscultation technologies designed to bring advanced cardiac detection into everyday clinical practice, the company claims. Eko Health is a pioneering AI early disease detection company advancing the way healthcare professionals detect and monitor heart and lung disease with its digital stethoscopes, ECG devices, software, and AI-powered analysis. Its U.S. Food and Drug Administration-cleared platform, with more than 700,000 devices sold worldwide, helps clinicians detect earlier and manage treatment more effectively to improve patient outcomes. Eko Health is headquartered in Emeryville, Calif.

Eko Health has appointed Dr Steven Steinhubl as Chief Medical Officer. The cardiologist and digital health leader will drive clinical strategy, research initiatives and scientific collaborations to strengthen the evidence base for AI-enabled cardiac detection across health systems worldwide. Dr Steinhubl is currently the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University. His research focuses on wearable sensor technologies, artificial intelligence in healthcare and virtual-first care delivery. The appointment follows significant momentum for Eko Health, including CMS finalising national payment for its SENSORA platform, publication of the TRICORDER study in The Lancet, and international expansion into the UK and Canada. The company has sold over 700,000 devices worldwide.

Boehringer Ingelheim and Eko Health inc. launch new AI-based solution that detects heart murmurs in dogs. Ingelheim, Germany and San Francisco, US, Wed, 29/04/2026 - 12:00 * Eko Vet+(TM) | CANINEBEAT(R) AI helps veterinarians detect, visualize, and grade heart murmurs in dogs that can otherwise go undetected * The CANINEBEAT(R) AI algorithm detects heart murmurs associated with structural heart disease in dogs with more than 95% sensitivity and specificity* * With earlier murmur detection, dogs can benefit from heart disease diagnostics and treatment sooner Boehringer Ingelheim, a global leader in animal health, and Eko Health, a leader in AI-powered cardiac and pulmonary disease detection, announced the launch of an innovative solution to detect, visualize, and grade heart murmurs in dogs. Eko Vet+(TM) | CANINEBEAT(R) AI aims to improve health outcomes for dogs with heart disease by enabling veterinarians to identify heart murmurs that might otherwise go unnoticed. "Our proprietary CANINEBEAT(R) AI algorithm integrated into the Eko Vet+(TM) app will powerfully support veterinarians' early detection of heart murmurs in dogs and pet owner conversations," said Dr. Erich Schött, Head of the Pet Business at Boehringer Ingelheim. "Heart murmur detection in dogs can be quite difficult, especially in busy clinics. Because pet owners don't see clinical signs in the early stage of heart disease, it's a challenge for veterinarians to explain that the dog suffers from a serious disease. With this unique AI solution, we can help detect murmurs earlier in the disease process, so dogs may receive appropriate diagnosis and treatment sooner." The new digital solution includes three integrated components: * The Eko CORE(TM) Digital Attachment connects to most single-tube stethoscopes and digitizes heart sounds that can then be analyzed by AI-based algorithms. It also helps veterinarians hear more subtle murmurs by amplifying heart sounds by 40 times and offers advanced noise cancellation and cardiac sound filtering. Other Eko devices also are compatible with the veterinary digital solution. * The CANINEBEAT(R) AI algorithm, trained and validated on more than 4,000 annotated canine heart sound recordings, detects heart murmurs associated with structural heart disease in dogs with more than 95% sensitivity and specificity.* The algorithm is intended to support veterinary clinical assessment and does not replace comprehensive cardiac evaluation or professional veterinary judgment. * The EkoVet+(TM) app incorporates insights from the CANINEBEAT(R) AI algorithm, including murmur images, sound files, and shareable reports. The app provides clinical support and helps veterinarians discuss the potential findings and any diagnostics and treatment needs with pet owners. Heart disease affects approximately 10% of all dogs.[1] The most common heart disease in dogs is myxomatous mitral valve disease (MMVD), which often produces a heart murmur when the heart has a leak in one of the heart valves, preventing blood from getting pumped correctly. MMVD is a chronic condition that is a major cause of morbidity and mortality in dogs.[2] Because dogs in early stages of heart disease may be asymptomatic, heart murmurs can go unnoticed during routine examinations. To address this challenge, 50 global veterinary cardiology experts contributed to the development of Eko Vet+TM with CANINEBEAT(R) AI. "CANINEBEAT(R) AI inside Eko Vet+(TM) is an exceptional resource for general practitioner veterinarians, helping them quickly detect and grade murmurs with a high level of consistency," said Prof. Gerhard Wess, Head of the Cardiology Service, Clinic for Small Animal Internal Medicine, Ludwig-Maximilians-Universität in Munich. "I am thrilled to be involved in the development of this new AI-powered solution that will give veterinarians greater confidence in heart murmur detection and support better outcomes for dogs." The introduction of this innovative auscultation solution for the veterinary industry has begun in the United States and the United Kingdom and will start in Germany next month. A phased expansion is planned in additional markets later this year and next. It will be available through both Boehringer Ingelheim and Eko Health, comprising the same three components through distinct commercial offers. "We've seen firsthand in human health how earlier, more accurate detection of cardiac disease can change the trajectory of care," said Connor Landgraf, CEO and co-founder of Eko Health. "Collaborating with Boehringer Ingelheim, a leader in canine cardiology, allows us to bring that same innovative approach to veterinary medicine. Together, we're equipping veterinarians with AI-powered tools to identify heart murmurs earlier and support better outcomes in canine patients." About Boehringer Ingelheim - Animal Health business. Boehringer Ingelheim provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals, and society. Learn more at www.boehringer-ingelheim.com/animal-health. About Boehringer Ingelheim. Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Its approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com. About Eko Health. Eko Health is a pioneering AI early disease detection company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, ECG devices, software, and AI-powered analysis. Its FDA-cleared platform, with more than 700,000 devices sold worldwide, helps clinicians detect earlier and manage treatment more effectively to improve patient outcomes. Eko Health is headquartered in Emeryville, California. For more information, visit www.ekohealth.com. Media contacts. Mi-Kyung Lee Lange [email protected] Sam Moore [email protected] Editorial note. * The CANINEBEAT study was conducted using one of the largest canine digital auscultation datasets to date, comprising more than 4,000 heart sound recordings collected from over 3,400 dogs. The study assessed the performance of the CANINEBEAT(R) AI algorithm in detecting canine heart murmurs. All recordings were systematically annotated, with the algorithm's development and validation supported by nearly 50 veterinary cardiology experts. Detailed study results will be presented and published in peer reviewed scientific forums. References. [1] Keene, Bruce W et al. "ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs." Journal of veterinary internal medicine vol. 33,3 (2019): 1127-1140. https://doi.org/10.1111/jvim.15488 [2] Häggström, J et al. "New insights into degenerative mitral valve disease in dogs." Veterinary Clinics of North America: Small Animal Practice. 2004 vol 34, 5: 1209-1226. doi: 10.1016/J.CVSM.2004.05.002. Mi-Kyung Lee-Lange Animal Health Communications Lead